Navigation Links
Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
Date:3/18/2009

million for the year ended December 31, 2007. Gross profit from continuing operations was $13.6 million or 57 percent for the year ended December 31, 2008 compared to $12.7 million or 55 percent for the year ended December 31, 2007. Operating expenses from continuing operations were $14.0 million for the year ended December 31, 2008 which included a $638,000 goodwill impairment and income from foreign currency revaluation of $1.0 million. Operating expenses from continuing operations for the year ended December 31, 2007 were $16.0 million, which included $1.5 million in restructuring charges for the year ended December 31, 2007. The Company used cash flows in operations of $413,000 for the year ended December 31, 2008 compared to cash flows used in operations of $2.9 million for the year ended December 31, 2007.

Comment and Outlook

Craig Tuttle, the Company's President and Chief Executive Officer, noted, "We are quite pleased with the overall results of the year. Our Molecular Reference Lab grew 70% in the year and we continued to make gains in our Pharmacogenomics services business by adding several key new pharma customers. With this growth in our services business, our previous significant effort in cost reduction and investment in our sales organization, we have achieved close to breakeven performance for the year."

"We continued to improve our operations efforts for our Molecular Reference Laboratory business as well as our WAVE system and reagent manufacturing activities. These efforts resulted in our lab gaining accreditation by the College of American Pathologists (CAP) and our manufacturing site attaining ISO9001:2000 accreditation during the fourth quarter."

"Most importantly, we embarked on an aggressive pursuit of new assay technology to drive both short and long-term growth for our laboratory businesses. Key licensing efforts during the year included our exclusive licenses with the
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Transgenomic, Inc. Forms Scientific Advisory Board
3. Transgenomic, Inc. Reports Third Quarter 2008 Results
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Chester, NJ (PRWEB) August 21, 2014 ... of personal selling optimization technology and services for ... publication of “Grading Pharma’s Use of New Commercial ... of Measurement & Analytics. , The article examines ... marketing yield that are being tested in the ...
(Date:8/20/2014)... Aug. 20, 2014 Clintrax Global, Inc., ... in Raleigh, NC , recently ... as Vice President of Administration. ... all corporate processes, including their alignment with company ... Brad worked as an HR executive, specializing in ...
(Date:8/20/2014)... High performance computing (HPC) will ... complete climate and Earth system model to address ... , Eight national laboratories, including Lawrence Livermore ... for Atmospheric Research, four academic institutions and one ... national laboratories include Argonne, Brookhaven, Lawrence Berkeley, Los ...
(Date:8/20/2014)... 2014 /PRNewswire-iReach/ -- A case study from Intel ... school,s bioengineering department and the Intel® Internet of ... Academic Program, UCSD,s research focuses on exploring the ... Photo - http://photos.prnewswire.com/prnh/20140819/137540 ... of Dr. Todd P. Coleman , Associate ...
Breaking Biology Technology:Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Clintrax Global, Inc. Announces Addition to Executive Team 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2
... today announced the,publication of an independent, peer reviewed, ... immune response measured prior to kidney,transplantation using the ... to identify patients that may be at risk ... in the first three,months following transplantation., The ...
... Naval Academy satellite called MidSTAR-1 have proven successful in ... that can check for harmful chemicals and the other ... These technologies were collaboratively developed between NASAs Goddard Space ... Field, Calif.; and Eclipse Energy Systems Inc. of various ...
... Brinks Hofer Gilson & Lione, one of,the largest ... to announce that Meredith Martin Addy has been named ... practice areas by Law & Politics,magazine., Intellectual property ... However, in fourteen years of practice, Ms. Addy is,among ...
Cached Biology Technology:New Independent Research Study Indicates That Cylex's ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection 2New Independent Research Study Indicates That Cylex's ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection 3NASA MidSTAR-1 successful technologies may be revolutionary 2NASA MidSTAR-1 successful technologies may be revolutionary 3NASA MidSTAR-1 successful technologies may be revolutionary 4Meredith Martin Addy Named One of Top 10 Illinois 'Super Lawyers' for 2008 2
(Date:8/20/2014)... 20, 2014 /CNW/ -  Issue Serious ... quickly become life threatening for some children.    ... million Canadians have food allergies and this number may be ... children are estimated to have food allergies.  ... irritations and hives to breathing difficulties and loss of consciousness. ...
(Date:8/20/2014)... in this image of the Para and Mato Grosso ... likely intentionally set in order to deforest the land. ... of trees where the land is thereafter converted to ... forestland to farms, ranches, or urban use. The herringbone-patterned ... Amazon Rainforest in the middle of the image are ...
(Date:8/20/2014)... Bay Area Lyme Foundation, which aims to make Lyme ... new research published in an upcoming issue of the ... . The findings show that ticks that carry ... year, making the threat of Lyme disease year-round. The ... Public Health (CDPH) Vector-borne Disease Section and University of ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... compounds beginning in early adulthood may delay the onset ... Wake Forest University School of Medicine and other centers ... the Endocrine Society, in San Diego. , Suppression of ... decrease cancer risk in those individuals at high risk ...
... University chemists have employed a computer simulation whose ... transcription process. The study, funded by the National ... issue of the Proceedings of the National Academy ... chromatin--a chromosome's substance consisting of histone proteins and ...
... can create tiny sensors with abilities to detect odors ... Pennsylvania and Monell Chemical Sciences Center. Their findings are ... Letters, a publication of the American Chemical Society. , ... detect molecules on the order of one part per ...
Cached Biology News:Suppressing growth hormone in early adulthood may prevent cancer 2Researchers Create DNA-Based Sensors for Nano-Tongues and Nano-Noses 2
Mouse monoclonal [H4B4] to LAMP2 - Lysosome Marker (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 3920 SwissProtID: P13473...
Mouse monoclonal [IA-C6] to MHC Class II I Ab + Ad (FITC) ( Abpromise for all tested applications). Antigen: Tissue / cell preparation of Purified Mouse lymph node B cells...
...
... Ciphergens ProteinChip System, Series 4000 incorporates the ... researchers and biologists in biomarker research. The ... fastest route for converting biomarker discoveries to ... The Series 4000 is designed to fit ...
Biology Products: